free email | research | news | portfolio | charts
 UBBFriend: Email This Page to Someone! |
 Investorville
 A
 Applied Molecular Evolution (AMEV)
|
| next newest topic | next oldest topic |
| Author | Topic: Applied Molecular Evolution (AMEV) |
|
InvestorGuide Daily Administrator |
posted 07-27-2000 06:21 PM
 
Biotech firm Applied Molecular Evolution (AMEV) priced at $19, opened at $25, closed at $30.88, and raised $88 million. |
|
Mayor of Investorville Administrator |
posted 05-19-2000 10:34 AM
This development-stage biotechnology firm improves genes and proteins for medical uses. Employing what it calsl directed evolution, the company adjusts a protein's amino acids one at a time until the protein acquires the desired therapuetic characteristics. AME's biopharmaceuticals have increased the potency of MedImmune's anti-tumor drug Vitaxin. Bristol-Meyers Squibb's AME-improved anti-tumor drug, BR96, has been licensed to Seattle Genetics for further development. The company plans to raise $85 million but an IPO date hasn't been set yet. (source: SEC filing) |
All times are EST (US) | next newest topic | next oldest topic |
  |
|
Powered by: Ultimate Bulletin Board, Version 5.43
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.
Press ctrl-D to bookmark this page for future reference.
By using this site you agree to our Terms of Use.
Copyright 1999 InvestorGuide.com Inc.